ABOVE: © ISTOCK.COM, ZORANM
Update (September 14): Oxford University and AstraZeneca announced Saturday, September 12, that they will be resuming their UK trials after a temporary pause following a case of transverse myelitis in a UK patient.
A series of late-stage clinical trials establishing the effectiveness and safety of a joint AstraZeneca and University of Oxford COVID-19 vaccine are on hold after one UK participant in a Phase 3 trial developed a severe and unexplained illness.
The incident was first reported on Tuesday (September 8) by STAT. The pause will delay results from one of the world’s largest COVID-19 vaccine development efforts. A company spokesperson says the measure has been taken out of an abundance of caution.
“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated,” AstraZeneca shared in a prepared statement. “We are ...
